Skip to main content
Premium Trial:

Request an Annual Quote

Quark Licenses Alnylam RNAi IP, Vows to End Opposition to IP in Europe, and Pens Deal With Pfizer

NEW YORK (GenomeWeb News) – Alnylam Pharmaceuticals has granted Quark Biotech licenses to discover, develop, and commercialize RNAi therapeutics targeting the RTP801 gene for age-related macular degeneration, the companies said yesterday.
Simultaneously, Quark has agreed to withdraw its support of opposition to the Kreutzer-Limmer patent estate currently granted in Europe.
Separately yesterday, Quark said that Pfizer has acquired an exclusive worldwide license to RTP801 and to molecules that modify its expression or function.
Financial terms of the Alnylam deal were not disclosed. However, the companies said they include upfront, annual, and milestone payments, as well as royalties on sales of any products covered by the deal.
Also yesterday SR Pharma said that its Atugen subsidiary will receive $95 million in milestone payments and royalties after collaborator Quark penned the Pfizer deal. Quark and Atugen developed RTP-801, Quark said.
SR Pharma said it will receive an initial payment of $2 million and a first milestone payment of $1.5 million on the start of the Phase I trial. All agreements are subject to certain conditions which include the clearance by the US Federal Trade Commission.
Based on pre-clinical models, it is believed that RNAi can treat AMD by blocking the expression of the RTP-801 gene.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.